protein kinase C inhibitors (Lilly)

N/A

Report date: 2025/03/20 20:00:06
NME

Base Information

Drug Nameprotein kinase C inhibitors (Lilly)
Drug Alias Nameprotein kinase C inhibitors (Martek)protein kinase C inhibitors (Sphinx)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionProtein kinase C inhibitors
TargetsProtein kinase C
Therapy Area/IndicationsInflammationDiabetes ComplicationsCardiovascular Diseases +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesSphinx Pharmaceuticals Itd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesMartek Biosciences CorpSphinx Pharmaceuticals ItdEli Lilly And Company
Active IndicationsN/A
Inactive IndicationsInflammationDiabetes ComplicationsCardiovascular Diseases +[4] 

Other Information

ATC CodeN/A
Related LinksN/A